home / stock / abbv / abbv articles

ABBV Articles, AbbVie Inc. - From 06/03/24

Stock Information
Company Name: AbbVie Inc.
Stock Symbol: ABBV
Market: NYSE
Website: abbvieinvestor.com
Menu
ABBV ABBV Quote ABBV Short ABBV News ABBV Articles ABBV Message Board
Get ABBV Alerts

News, Short Squeeze, Breakout and More Instantly...
AbbVie Skyrizi Gets CHMP Nod for Ulcerative Colitis in EU | Benzinga

AbbVie (NYSE: ABBV) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has a...
TJX, Sysco, Lululemon And A Healthcare Stock On CNBC's 'Final Trades' | Benzinga

On CNBC's “Halftime Report Final Trades,” Brenda Vingiello of Sand Hill Global Advisors named The TJX Companies, Inc. (NYSE:TJX) a...

After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information Stolen In Data Breach In February | Benzinga

U.S. drug wholesaler Cencora Inc (NYSE:COR), formerly AmerisourceBergen, is notifying affected individuals about their personal...

Cannabis Meets Prescription Drugs, Steroids And Ketamine In Schedule III: What It Means, Key Stocks To Watch | Benzinga

President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA)...
AbbVie Is 'Successfully Positioned To Absorb Humira Biosimilar Erosion': Analyst | Benzinga

Cantor Fitzgerald has initiated coverage on AbbVie Inc (NYSE:ABBV), a global pharma company. The analyst notes that the company has ...

$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,000 Today | Benzinga

AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 1.96% on an annualized basis producing an average annual return of 15.08%. ...

Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In | Benzinga

Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028. This gr...
$1000 Invested In This Stock 10 Years Ago Would Be Worth $3,100 Today | Benzinga

AbbVie (NYSE:ABBV) has outperformed the market over the past 10 years by 1.32% on an annualized basis producing an average annual return of 11.69%....

Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week | Benzinga

Corporate earnings came to the market’s rescue in the past week, helping to overcome rate fears. As we look ahead to the unfolding week, it r...

Arthritis Patients - Cigna's Evernorth To Offer Humira Biosimilar At No Out-of-Pocket Cost | Benzinga

On Thursday, Evernorth Health Services said its Accredo arm will make a Humira biosimilar available to patients with no out-of-pocket costs. Eve...
Previous 10 Next 10